表紙：併用療法薬の2030年までの市場予測：タイプ別、剤形別、用途別、エンドユーザー別、地域別の世界分析

市場調査レポート

商品コード

1383367

併用療法薬の2030年までの市場予測：タイプ別、剤形別、用途別、エンドユーザー別、地域別の世界分析

Combination Therapy Drug Treatment Market Forecasts to 2030 - Global Analysis By Type (Interferon and Nucleoside Drugs, Targeted Therapies Drugs, Diammonium Glycyrrhizinate and Other Types), Drug Form, Application, End User and By Geography

出版日: 2023年11月01日 | 発行: Stratistics Market Research Consulting

| ページ情報: 英文 200+ Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,150 650,097円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 822,412円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 994,727円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,174,875円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.65円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界の併用療法薬市場は2023年に1,972億米ドルを占め、予測期間中のCAGRは9.2%で、2030年には3,651億米ドルに達すると予測されています。

併用療法とは、特定の疾患や病状を治療するために、2種類以上の薬剤や治療薬を同時または逐次投与する医療戦略です。併用療法は、がん、感染症、心血管疾患、その他多くの医療分野で応用されています。薬剤の組み合わせは、悪影響を抑えながら効果を最大化する可能性があります。

医薬品開発における技術の進歩

併用療法の分野は、創薬における技術開発によって大きく改善され、多くの医学的疾患の治療に多くの利点をもたらしています。ゲノミクスや分子プロファイリングのような技術開発により、患者特有の遺伝子プロファイルに基づいて併用薬を調整することが可能になっています。これにより、患者や疾患特有の性質に基づき、副作用を最小限に抑えつつ効果を最大化する個別化治療が可能になります。予測期間中、これはおそらく市場の発展に役立つと思われます。

副作用の増加

様々な薬を併用する中で、副作用や否定的な反応が起こる可能性が高まるかもしれないです。患者はより強い薬物相互作用や副作用に遭遇し、治療が耐え難いものになるかもしれないです。薬剤の併用は累積毒性を引き起こす可能性があり、これは特定の化学物質が徐々に体内に蓄積され、臓器障害やその他の悪影響をもたらす可能性がある状態です。これが市場拡大を妨げる主な問題です。

利点に対する意識の高まり

併用療法とは、特定の病気や病状を治療するために2種類以上の薬剤を使用することです。治療効果の向上や副作用の軽減など、多くの利点があります。複数の薬剤が相乗的に作用し、多くの疾患関連因子を標的とすることは重要な利点の一つであり、その結果、より良い結果が得られることが多いです。さらに、複数の薬剤を併用することで、必要な個々の投与量を減らすことができ、副作用を減らし、患者の治療コンプライアンスを向上させることができます。これらのことが、マケットの成長に影響を与える要因となっています。

コストの上昇

様々な薬剤の使用により、治療費全体が大幅に上昇する可能性があります。特定の個人、特に医療資源に制約のあるヘルスケア・システムでは、これがアクセスの障壁となる可能性があります。特に、社会化されたヘルスケアや公的支援を受ける国々では、併用薬の高額な費用はヘルスケアシステムに負担をかけることになります。政府は、費用対効果や財政上の制約から、どの治療薬を処方箋に含めるかについて難しい選択を迫られることが多いです。これが市場拡大を制限する要素となっています。

COVID-19の影響：

COVID-19に邪魔されたとき、併用療法の臨床試験が行われていました。パンデミックによりいくつかの臨床試験が中断または延期されたため、将来的な医薬品承認のスケジュールや最先端治療への患者のアクセスに影響を及ぼしました。パンデミックは、世界の医薬品供給網の弱点を明らかにしました。医薬品の製造と流通が途絶えたため、一部の地域ではいくつかの併用治療薬が不足しました。

予測期間中、グリチルリチン酸二アンモニウム・セグメントが最大となる見込み

予測期間中、グリチルリチン酸二アンモニウム・セグメントが最大となる見込み。グリチルリチン酸ジアンモニウム（DAG）は植物成長調整剤です。DAGは甘草の根に天然に存在し、風邪や咳を治すために伝統的な漢方薬として用いられています。DAGは、抗炎症薬としての可能性が研究されてきたが、すでに市販されている非ステロイド性抗炎症薬の上位品との差別化を示すことはできなかっています。

予測期間中、CAGRが最も高いのは心血管疾患セグメントである

予測期間中、CAGRが最も高くなると予想されるのは心血管疾患セグメントです。併用療法は、心臓と血管の健康をいくつかの側面から管理・治療する方法です。作用機序の異なる複数の薬剤を使用します。この戦略は、高血圧、高コレステロール、血栓形成などの心血管障害の危険因子を治療するために頻繁に使用されます。スタチンや抗血小板剤のような薬剤の使用は、心血管疾患に対する併用療法の一般的な構成要素です。

最大のシェアを占める地域

予測期間中、北米が最大の市場シェアを占めると予測されます。バイオテクノロジー企業、学術機関、研究機関は、創薬と研究開発における共同努力を通じて、この産業の拡大にも貢献しています。新薬の併用療法に対する要望は、併用療法の利点に関する社会的認知の高まり、がん、糖尿病、心血管疾患などの慢性疾患の罹患率の上昇、医薬品研究開発の改善などの原因によって高まっています。

CAGRが最も高い地域：

予測期間中、アジア太平洋地域のCAGRが最も高いと予測されます。がん、糖尿病、心血管疾患などの慢性疾患の負担は、この地域全体で増加しています。複雑な疾患の治療には、薬剤の組み合わせがますます重要になってきています。この地域の多くの国々は、医療研究とインフラへの支出を拡大しており、これが併用治療薬の創出と普及を後押ししています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレーヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第11章企業プロファイル

WebMD LLC
CSL Ltd
Grifols S.A
Baxalta Incorporated
Octapharma AG
Kedrion S.p.A
China Biologic Products
Roche
Pfizer
Eli Lilly
Johnson & Johnson
Novartis
Gilead Sciences
AstraZeneca
Merck & Co.
Sanofi

図表

List of Tables

Table 1 Global Combination Therapy Drug Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Combination Therapy Drug Market Outlook, By Type (2021-2030) ($MN)
Table 3 Global Combination Therapy Drug Market Outlook, By Interferon and Nucleoside Drugs (2021-2030) ($MN)
Table 4 Global Combination Therapy Drug Market Outlook, By Targeted Therapies Drugs (2021-2030) ($MN)
Table 5 Global Combination Therapy Drug Market Outlook, By Diammonium Glycyrrhizinate (2021-2030) ($MN)
Table 6 Global Combination Therapy Drug Market Outlook, By Other Types (2021-2030) ($MN)
Table 7 Global Combination Therapy Drug Market Outlook, By Drug Form (2021-2030) ($MN)
Table 8 Global Combination Therapy Drug Market Outlook, By Liquid (2021-2030) ($MN)
Table 9 Global Combination Therapy Drug Market Outlook, By Solid (2021-2030) ($MN)
Table 10 Global Combination Therapy Drug Market Outlook, By Application (2021-2030) ($MN)
Table 11 Global Combination Therapy Drug Market Outlook, By Cancer (2021-2030) ($MN)
Table 12 Global Combination Therapy Drug Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
Table 11 Global Combination Therapy Drug Market Outlook, By Immune Disease (2021-2030) ($MN)
Table 14 Global Combination Therapy Drug Market Outlook, By Other Applications (2021-2030) ($MN)
Table 15 Global Combination Therapy Drug Market Outlook, By End User (2021-2030) ($MN)
Table 16 Global Combination Therapy Drug Market Outlook, By Clinic (2021-2030) ($MN)
Table 17 Global Combination Therapy Drug Market Outlook, By Hospital (2021-2030) ($MN)
Table 18 Global Combination Therapy Drug Market Outlook, By Other End Users (2021-2030) ($MN)
Table 19 North America Combination Therapy Drug Market Outlook, By Country (2021-2030) ($MN)
Table 20 North America Combination Therapy Drug Market Outlook, By Type (2021-2030) ($MN)
Table 21 North America Combination Therapy Drug Market Outlook, By Interferon and Nucleoside Drugs (2021-2030) ($MN)
Table 22 North America Combination Therapy Drug Market Outlook, By Targeted Therapies Drugs (2021-2030) ($MN)
Table 23 North America Combination Therapy Drug Market Outlook, By Diammonium Glycyrrhizinate (2021-2030) ($MN)
Table 24 North America Combination Therapy Drug Market Outlook, By Other Types (2021-2030) ($MN)
Table 25 North America Combination Therapy Drug Market Outlook, By Drug Form (2021-2030) ($MN)
Table 26 North America Combination Therapy Drug Market Outlook, By Liquid (2021-2030) ($MN)
Table 27 North America Combination Therapy Drug Market Outlook, By Solid (2021-2030) ($MN)
Table 28 North America Combination Therapy Drug Market Outlook, By Application (2021-2030) ($MN)
Table 29 North America Combination Therapy Drug Market Outlook, By Cancer (2021-2030) ($MN)
Table 30 North America Combination Therapy Drug Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
Table 31 North America Combination Therapy Drug Market Outlook, By Immune Disease (2021-2030) ($MN)
Table 32 North America Combination Therapy Drug Market Outlook, By Other Applications (2021-2030) ($MN)
Table 33 North America Combination Therapy Drug Market Outlook, By End User (2021-2030) ($MN)
Table 34 North America Combination Therapy Drug Market Outlook, By Clinic (2021-2030) ($MN)
Table 35 North America Combination Therapy Drug Market Outlook, By Hospital (2021-2030) ($MN)
Table 36 North America Combination Therapy Drug Market Outlook, By Other End Users (2021-2030) ($MN)
Table 37 Europe Combination Therapy Drug Market Outlook, By Country (2021-2030) ($MN)
Table 38 Europe Combination Therapy Drug Market Outlook, By Type (2021-2030) ($MN)
Table 39 Europe Combination Therapy Drug Market Outlook, By Interferon and Nucleoside Drugs (2021-2030) ($MN)
Table 40 Europe Combination Therapy Drug Market Outlook, By Targeted Therapies Drugs (2021-2030) ($MN)
Table 41 Europe Combination Therapy Drug Market Outlook, By Diammonium Glycyrrhizinate (2021-2030) ($MN)
Table 42 Europe Combination Therapy Drug Market Outlook, By Other Types (2021-2030) ($MN)
Table 43 Europe Combination Therapy Drug Market Outlook, By Drug Form (2021-2030) ($MN)
Table 44 Europe Combination Therapy Drug Market Outlook, By Liquid (2021-2030) ($MN)
Table 45 Europe Combination Therapy Drug Market Outlook, By Solid (2021-2030) ($MN)
Table 46 Europe Combination Therapy Drug Market Outlook, By Application (2021-2030) ($MN)
Table 47 Europe Combination Therapy Drug Market Outlook, By Cancer (2021-2030) ($MN)
Table 48 Europe Combination Therapy Drug Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
Table 49 Europe Combination Therapy Drug Market Outlook, By Immune Disease (2021-2030) ($MN)
Table 50 Europe Combination Therapy Drug Market Outlook, By Other Applications (2021-2030) ($MN)
Table 51 Europe Combination Therapy Drug Market Outlook, By End User (2021-2030) ($MN)
Table 52 Europe Combination Therapy Drug Market Outlook, By Clinic (2021-2030) ($MN)
Table 53 Europe Combination Therapy Drug Market Outlook, By Hospital (2021-2030) ($MN)
Table 54 Europe Combination Therapy Drug Market Outlook, By Other End Users (2021-2030) ($MN)
Table 55 Asia Pacific Combination Therapy Drug Market Outlook, By Country (2021-2030) ($MN)
Table 56 Asia Pacific Combination Therapy Drug Market Outlook, By Type (2021-2030) ($MN)
Table 57 Asia Pacific Combination Therapy Drug Market Outlook, By Interferon and Nucleoside Drugs (2021-2030) ($MN)
Table 58 Asia Pacific Combination Therapy Drug Market Outlook, By Targeted Therapies Drugs (2021-2030) ($MN)
Table 59 Asia Pacific Combination Therapy Drug Market Outlook, By Diammonium Glycyrrhizinate (2021-2030) ($MN)
Table 60 Asia Pacific Combination Therapy Drug Market Outlook, By Other Types (2021-2030) ($MN)
Table 61 Asia Pacific Combination Therapy Drug Market Outlook, By Drug Form (2021-2030) ($MN)
Table 62 Asia Pacific Combination Therapy Drug Market Outlook, By Liquid (2021-2030) ($MN)
Table 63 Asia Pacific Combination Therapy Drug Market Outlook, By Solid (2021-2030) ($MN)
Table 64 Asia Pacific Combination Therapy Drug Market Outlook, By Application (2021-2030) ($MN)
Table 65 Asia Pacific Combination Therapy Drug Market Outlook, By Cancer (2021-2030) ($MN)
Table 66 Asia Pacific Combination Therapy Drug Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
Table 67 Asia Pacific Combination Therapy Drug Market Outlook, By Immune Disease (2021-2030) ($MN)
Table 68 Asia Pacific Combination Therapy Drug Market Outlook, By Other Applications (2021-2030) ($MN)
Table 69 Asia Pacific Combination Therapy Drug Market Outlook, By End User (2021-2030) ($MN)
Table 70 Asia Pacific Combination Therapy Drug Market Outlook, By Clinic (2021-2030) ($MN)
Table 71 Asia Pacific Combination Therapy Drug Market Outlook, By Hospital (2021-2030) ($MN)
Table 72 Asia Pacific Combination Therapy Drug Market Outlook, By Other End Users (2021-2030) ($MN)
Table 73 South America Combination Therapy Drug Market Outlook, By Country (2021-2030) ($MN)
Table 74 South America Combination Therapy Drug Market Outlook, By Type (2021-2030) ($MN)
Table 75 South America Combination Therapy Drug Market Outlook, By Interferon and Nucleoside Drugs (2021-2030) ($MN)
Table 76 South America Combination Therapy Drug Market Outlook, By Targeted Therapies Drugs (2021-2030) ($MN)
Table 77 South America Combination Therapy Drug Market Outlook, By Diammonium Glycyrrhizinate (2021-2030) ($MN)
Table 78 South America Combination Therapy Drug Market Outlook, By Other Types (2021-2030) ($MN)
Table 79 South America Combination Therapy Drug Market Outlook, By Drug Form (2021-2030) ($MN)
Table 80 South America Combination Therapy Drug Market Outlook, By Liquid (2021-2030) ($MN)
Table 81 South America Combination Therapy Drug Market Outlook, By Solid (2021-2030) ($MN)
Table 82 South America Combination Therapy Drug Market Outlook, By Application (2021-2030) ($MN)
Table 83 South America Combination Therapy Drug Market Outlook, By Cancer (2021-2030) ($MN)
Table 84 South America Combination Therapy Drug Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
Table 85 South America Combination Therapy Drug Market Outlook, By Immune Disease (2021-2030) ($MN)
Table 86 South America Combination Therapy Drug Market Outlook, By Other Applications (2021-2030) ($MN)
Table 87 South America Combination Therapy Drug Market Outlook, By End User (2021-2030) ($MN)
Table 88 South America Combination Therapy Drug Market Outlook, By Clinic (2021-2030) ($MN)
Table 89 South America Combination Therapy Drug Market Outlook, By Hospital (2021-2030) ($MN)
Table 90 South America Combination Therapy Drug Market Outlook, By Other End Users (2021-2030) ($MN)
Table 91 Middle East & Africa Combination Therapy Drug Market Outlook, By Country (2021-2030) ($MN)
Table 92 Middle East & Africa Combination Therapy Drug Market Outlook, By Type (2021-2030) ($MN)
Table 93 Middle East & Africa Combination Therapy Drug Market Outlook, By Interferon and Nucleoside Drugs (2021-2030) ($MN)
Table 94 Middle East & Africa Combination Therapy Drug Market Outlook, By Targeted Therapies Drugs (2021-2030) ($MN)
Table 95 Middle East & Africa Combination Therapy Drug Market Outlook, By Diammonium Glycyrrhizinate (2021-2030) ($MN)
Table 96 Middle East & Africa Combination Therapy Drug Market Outlook, By Other Types (2021-2030) ($MN)
Table 97 Middle East & Africa Combination Therapy Drug Market Outlook, By Drug Form (2021-2030) ($MN)
Table 98 Middle East & Africa Combination Therapy Drug Market Outlook, By Liquid (2021-2030) ($MN)
Table 99 Middle East & Africa Combination Therapy Drug Market Outlook, By Solid (2021-2030) ($MN)
Table 100 Middle East & Africa Combination Therapy Drug Market Outlook, By Application (2021-2030) ($MN)
Table 101 Middle East & Africa Combination Therapy Drug Market Outlook, By Cancer (2021-2030) ($MN)
Table 102 Middle East & Africa Combination Therapy Drug Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
Table 103 Middle East & Africa Combination Therapy Drug Market Outlook, By Immune Disease (2021-2030) ($MN)
Table 104 Middle East & Africa Combination Therapy Drug Market Outlook, By Other Applications (2021-2030) ($MN)
Table 105 Middle East & Africa Combination Therapy Drug Market Outlook, By End User (2021-2030) ($MN)
Table 106 Middle East & Africa Combination Therapy Drug Market Outlook, By Clinic (2021-2030) ($MN)
Table 107 Middle East & Africa Combination Therapy Drug Market Outlook, By Hospital (2021-2030) ($MN)
Table 108 Middle East & Africa Combination Therapy Drug Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC24217

According to Stratistics MRC, the Global Combination Therapy Drug Market is accounted for $197.2 billion in 2023 and is expected to reach $365.1 billion by 2030 growing at a CAGR of 9.2% during the forecast period. Combination therapy is a medical treatment strategy that entails the simultaneous or sequential administration of two or more medications or therapeutic agents to treat a particular illness or medical condition. Combination treatment has applications in cancer, infectious disorders, cardiovascular issues, and more areas of medicine. The combination of the medications may maximize effectiveness while reducing negative effects.

Market Dynamics:

Driver:

Technological advancements in drug development

The field of combination therapy has been greatly improved by technological developments in drug creation, giving a number of benefits in the treatment of many medical diseases. Technological developments like genomics and molecular profiling enable combination medicines to be tailored based on a patient's particular genetic profile. This allows for individualized treatment that maximizes efficacy while minimizing negative effects based on the unique qualities of the patient and the ailment. Over the projection period, this is probably going to help the market develop.

Restraint:

Increased side effects

The chance of side effects or negative reactions may rise while taking various medications together. Patients encounter stronger medication interactions or adverse effects, which might make the therapy less tolerable. Combining medications can result in cumulative toxicity, a condition in which the body gradually builds up more of a particular chemical, perhaps resulting in organ damage or other negative effects. This is the main issue impeding market expansion.

Opportunity:

Growing awareness about the benefits

Combination treatment is the use of two or more medications to treat a specific illness or medical condition. It has a number of benefits chief among them improved therapeutic effectiveness and fewer adverse effects. Multiple medications acting synergistically to target many disease-related factors are one important advantage, which frequently results in better results. Additionally, combining medications can reduce the necessary individual dosages, decreasing adverse effects and improving patient compliance with therapy. These are the factors influencing the growth of the maket.

Threat:

Higher costs

The cost of therapy as a whole can be greatly raised by the usage of various medications. For certain individuals, especially in healthcare systems with constrained resources, this might be a barrier to access. Particularly in nations with socialized or publicly supported healthcare, the high expense of combination medicines can put a burden on healthcare systems. Governments frequently have to make difficult choices about which treatments to include in their formularies due to cost-effectiveness and financial restrictions. This is the element limiting market expansion.

COVID-19 Impact:

Clinical studies for combination treatments were being conducted when COVID-19 disturbed them. The pandemic caused several trials to be either suspended or postponed, which had an impact on the schedule for prospective medication approvals and patient access to cutting-edge therapies. The epidemic revealed weaknesses in the world's medicine supply networks. There were shortages of several combination treatment medications in some areas due to disruptions in pharmaceutical manufacture and distribution.

The diammonium glycyrrhizinate segment is expected to be the largest during the forecast period

The diammonium glycyrrhizinate segment is expected to be the largest during the forecast period. Diammonium glycyrrhizinate (DAG) is a plant growth regulator. It is naturally present in licorice plant roots, which are used in traditional Chinese medicine to cure colds and coughs. DAG has been investigated for its potential as an anti-inflammatory medication, however it failed to demonstrate any appreciable distinction from the top non-steroidal anti-inflammatory medications already on the market.

The cardiovascular disease segment is expected to have the highest CAGR during the forecast period

The cardiovascular disease segment is expected to have the highest CAGR during the forecast period. Combination treatment is a method for managing and treating several aspects of heart and vascular health. It uses a number of medications with varied modes of action. This strategy is frequently used to treat risk factors for cardiovascular disorders, such as high blood pressure, high cholesterol, and blood clot formation. Utilizing drugs like statins and antiplatelet agents is a common component of combination therapy for cardiovascular disease.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Through their joint efforts in medication discovery and development, biotechnology companies, academic institutions, and research organizations also contribute to the expansion of this industry. The desire for novel combination medicines is being driven by causes such as rising public knowledge of the advantages of combination therapy, rising rates of chronic illnesses including cancer, diabetes, and cardiovascular problems, and improvements in pharmaceutical research and development.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The burden of chronic illnesses including cancer, diabetes, and cardiovascular conditions was growing throughout the area. Drug combinations were becoming increasingly important for treating complicated medical disorders. Many nations in the area were expanding their expenditures on medical research and infrastructure, which aided in the creation and uptake of combination treatment medications.

Key players in the market

Some of the key players in Combination Therapy Drug market include: WebMD LLC, CSL Ltd, Grifols S.A, Baxalta Incorporated, Octapharma AG, Kedrion S.p.A, China Biologic Products, Roche, Pfizer, Eli Lilly, Johnson & Johnson, Novartis, Gilead Sciences, AstraZeneca, Merck & Co. and Sanofi.

Key Developments:

In July 2023, Flagship Pioneering, Inc. and Pfizer Inc. announced the companies have partnered to create a new pipeline of innovative medicines. Under the terms of the novel agreement, Flagship and Pfizer will each invest $50M upfront to explore opportunities to develop 10 single-asset programs.

In November 2022, Arcturus Therapeutics Holdings Inc. announced a strategic collaboration with CSL Seqirus. CSL Seqirus' vaccine portfolio includes the world's second largest influenza vaccine franchise. CSL Seqirus is part of CSL Limited

In September 2022, WebMD Health Services announced a new partnership with Fern Health, a leading digital platform giving employees and health plan members the guidance and tools they need to address the underlying causes of persistent pain.

Types Covered:

Interferon and Nucleoside Drugs
Targeted Therapies Drugs
Diammonium Glycyrrhizinate
Other Types

Drug Forms Covered:

Liquid
Solid

Applications Covered:

Cancer
Cardiovascular Disease
Immune Disease
Other Applications

End Users Covered:

Clinic
Hospital
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Combination Therapy Drug Market, By Type

5.1 Introduction
5.2 Interferon and Nucleoside Drugs
5.3 Targeted Therapies Drugs
5.4 Diammonium Glycyrrhizinate
5.5 Other Types

6 Global Combination Therapy Drug Market, By Drug Form

6.1 Introduction
6.2 Liquid
6.3 Solid

7 Global Combination Therapy Drug Market, By Application

7.1 Introduction
7.2 Cancer
7.3 Cardiovascular Disease
7.4 Immune Disease
7.5 Other Applications

8 Global Combination Therapy Drug Market, By End User

8.1 Introduction
8.2 Clinic
8.3 Hospital
8.4 Other End Users

9 Global Combination Therapy Drug Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 WebMD LLC
11.2 CSL Ltd
11.3 Grifols S.A
11.4 Baxalta Incorporated
11.5 Octapharma AG
11.6 Kedrion S.p.A
11.7 China Biologic Products
11.8 Roche
11.9 Pfizer
11.10 Eli Lilly
11.11 Johnson & Johnson
11.12 Novartis
11.13 Gilead Sciences
11.14 AstraZeneca
11.15 Merck & Co.
11.16 Sanofi